Researchers found that a new interferon-free combination therapy cleared the hepatitis C virus in 93 percent of patients with liver cirrhosis who had not been previously treated. The experimental drug combination includes three drugs in the pipeline – daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). According to researchers at Duke Medicine, a …